RavenQuest BioMed (CSE:RQB; OTCQB:RVVQF) issued a corporate update to shareholders of the company.

As quoted in the press release:


Operational Activity

RavenQuest’s Investment Division has added two new projects at the MOU stage, including a 250,000 square foot joint venture with Fort McMurray #468 First Nation and the acquisition of late-stage applicant, Western AgriPharma Limited, with 125,000 square feet of future grow space. Full buildout of both facilities moves RavenQuest’s projected production from 11,000 [kilograms] annually to over 50,000 [kilograms] annually.

RavenQuest has signed a lease for space in downtown Edmonton aimed at opening its flagship retail recreational cannabis store, with application for license to be submitted near term. The retail space is strategically situated within close proximity to Edmonton’s downtown nightlife, concert halls, conference center, public transit and the popular “ICE District”, home to NHL hockey and a densely populated residential area. RavenQuest has designed a unique retail experience which includes significant space dedicated to education and awareness surrounding cannabis consumption.

RavenQuest’s Greater Toronto facility, Bloomera, currently has a license to cultivate and has completed the first of two harvests required by Health Canada for license to sell and dispense. Bloomera successfully passed all chemistry and microbiology testing on the first grow cycle, expects to complete the second and acquire sell/dispense license by July, 2018.

Click here to read the full press release.

Source: globenewswire.com

Appointment of Dr. Kelmendi, Assistant Professor of Psychiatry at Yale University and co-founder of the Yale Psychedelic Science Group, brings another experienced medical professional to Lobe’s advisory team.

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the appointment of Benjamin Kelmendi, MD, Assistant Professor of Psychiatry at Yale University School of Medicine, to its Scientific Advisory Board.

Keep reading... Show less

Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or ” Ayurcann “), a Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to unveil further details of its Phase 2 expansion plans.

Ayurcann has commenced trading on the Canadian Securities Exchange (” CSE “) on April 8, 2021 and subsequently announced a private placement of up to $500,000 (” Financing “), as per the Company’s press release dated April 12, 2021. The proceeds of the Financing are intended to be used to further pursue Phase 2 of the expansion of the production capacity of the Company’s Pickering facility.

Keep reading... Show less

New findings suggest the COVID-19 pandemic, combined with expanded state legalization, has attracted new consumers to the category and accelerated cannabis acceptance and adoption.

  • YouGov study indicates the number of current cannabis consumers has increased 56% within just two years compared to the 16% of Americans who reported current consumption in 2018.
  • 23% of current consumers say they tried cannabis for the first time within the past year.
  • More than half of cannabis consumers say they will purchase or try a new product or format this 420, indicating that the holiday is becoming increasingly focused on exploration and trial.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or the “Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, released the results of a survey today showing one in four Americans currently consume cannabis, reporting they’ve tried some form of cannabis within the past twelve months. That’s a significant increase since 2018* when just 16% of U.S. adults reported current consumption, representing a 56% increase in just two years. What’s more, 23% of current cannabis consumers say they tried cannabis for the first time over the past year, suggesting the COVID-19 pandemic, combined with expanded state legalization, has rapidly accelerated cannabis acceptance and adoption in America.

Keep reading... Show less

Acquires Three Operating Dispensaries in Northeast Pennsylvania

Purchase price represents a mid-single digit multiple of KCR’s expected 2021 EBITDA

Keep reading... Show less